Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744811 | 1.00 | GNAI3 (0.49) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL15731364 | 1.00 | GNAI3 (0.49) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL3402450 | 0.89 | MEN1 (0.46) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL3402896 | 0.89 | MEN1 (0.46) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL3399867 | 0.89 | MEN1 (0.46) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL11717 | 0.88 | GNAI3 (0.61) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL22474753 | 0.87 | EPHX2 (0.45) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL13459961 | 0.85 | GNAI3 (0.58) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL14275539 | 0.85 | GNAI3 (0.58) | GNAI3GNAO1GNAI1CHRNB2CHRNA3 | |
| SCHEMBL3403409 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2020-04-16 | — | — | US | disclosed |
| CN-103282025-A | Melt-extruded solid dispersions containing apoptosis-inducing agents | ABBVIE INC | 2013-09-04 | — | — | CN | disclosed |
| CN-103167867-A | Solid dispersions containing an apoptosis-inducing agent | ABBOTT LAB | 2013-06-19 | — | — | CN | disclosed |
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| CN-102448959-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | GNAI3 3792/4885GNAO1 1362/4885GNAI1 3585/4885 |
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | GNAI3 3792/4885GNAO1 1362/4885GNAI1 3585/4885 |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | GNAI3 392/4885GNAO1 2249/4885GNAI1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.